Editas Medicine, Inc. (EDIT)
3.00
-0.11
(-3.54%)
USD |
NASDAQ |
Aug 24, 16:00
3.00
0.00 (0.00%)
After-Hours: 20:00
Editas Medicine Net Income (Quarterly) : -18.23M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -18.23M |
| March 31, 2026 | -24.98M |
| December 31, 2025 | -5.62M |
| September 30, 2025 | -25.12M |
| June 30, 2025 | -53.24M |
| March 31, 2025 | -76.09M |
| December 31, 2024 | -45.40M |
| September 30, 2024 | -62.14M |
| June 30, 2024 | -67.61M |
| March 31, 2024 | -61.95M |
| December 31, 2023 | -18.87M |
| September 30, 2023 | -45.02M |
| June 30, 2023 | -40.29M |
| March 31, 2023 | -49.04M |
| December 31, 2022 | -60.74M |
| September 30, 2022 | -55.73M |
| June 30, 2022 | -53.45M |
| March 31, 2022 | -50.52M |
| December 31, 2021 | -41.44M |
| September 30, 2021 | -39.08M |
| June 30, 2021 | -55.26M |
| March 31, 2021 | -56.73M |
| December 31, 2020 | -62.50M |
| Date | Value |
|---|---|
| September 30, 2020 | 7.819M |
| June 30, 2020 | -23.57M |
| March 31, 2020 | -37.72M |
| December 31, 2019 | -37.77M |
| September 30, 2019 | -32.94M |
| June 30, 2019 | -33.79M |
| March 31, 2019 | -29.25M |
| December 31, 2018 | -25.05M |
| September 30, 2018 | -15.24M |
| June 30, 2018 | -38.72M |
| March 31, 2018 | -30.94M |
| December 31, 2017 | -36.19M |
| September 30, 2017 | -26.60M |
| June 30, 2017 | -26.44M |
| March 31, 2017 | -31.10M |
| December 31, 2016 | -39.38M |
| September 30, 2016 | -21.02M |
| June 30, 2016 | -19.04M |
| March 31, 2016 | -17.74M |
| December 31, 2015 | -12.63M |
| September 30, 2015 | -7.405M |
| June 30, 2015 | -47.57M |
| March 31, 2015 | -5.291M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Geron Corp. | -16.68M |
| Novavax, Inc. | -53.39M |
| Recursion Pharmaceuticals, Inc. | -131.00M |
| Agenus, Inc. | -0.567M |
| Amgen, Inc. | 2.375B |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 11.89M |
| Total Expenses (Quarterly) | 30.12M |
| EPS Diluted (Quarterly) | -0.1528 |
| Enterprise Value | 337.09M |
| Gross Profit Margin (Quarterly) | 96.50% |
| Profit Margin (Quarterly) | -153.3% |
| Earnings Yield | -24.82% |
| Normalized Earnings Yield | -26.59 |